GIRK4 inhibitor for atrial fibrillation
搜索文档
BAYER INITIATES PHASE II STUDY OF INVESTIGATIONAL GIRK4 INHIBITOR IN PATIENTS WITH ATRIAL FIBRILLATION
Businesswire· 2026-09-09 19:42
拜耳启动心房颤动新药II期临床 - 拜耳宣布启动一项全球II期临床试验(NCT07625215)[1] - 该试验评估BAY 3670549，一种高选择性GIRK4抑制剂[1] - 该药物具有控制心房颤动患者心脏细胞电活动的新潜力[1] - 试验为随机、双盲、安慰剂对照、平行组、单次治疗研究[1]
